array(40) {
  [0]=>
  string(4) "9213"
  ["article_id"]=>
  string(4) "9213"
  [1]=>
  string(97) "MilliporeSigma and ACD/Labs in collaboration to 'shape the future of analytical testing' "
  ["article_title"]=>
  string(97) "MilliporeSigma and ACD/Labs in collaboration to 'shape the future of analytical testing' "
  [2]=>
  string(150) "Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Me"
  ["short_description"]=>
  string(150) "Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Me"
  [3]=>
  string(159) "Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA."
  ["description"]=>
  string(159) "Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(173) "https://www.outsourcing-pharma.com/Article/2024/01/10/milliporesigma-and-acd-labs-in-collaboration-for-chemtwins-platform?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(173) "https://www.outsourcing-pharma.com/Article/2024/01/10/milliporesigma-and-acd-labs-in-collaboration-for-chemtwins-platform?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-10 18:47:00"
  ["add_date"]=>
  string(19) "2024-01-10 18:47:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:49"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9095"
  ["article_id"]=>
  string(4) "9095"
  [1]=>
  string(126) "Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX on Male Fertility"
  ["article_title"]=>
  string(126) "Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX on Male Fertility"
  [2]=>
  string(174) "&#nl&#nl&#nl&#nl&#nl&#nl&#nl&#nlRALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone defic"
  ["short_description"]=>
  string(174) "&#nl&#nl&#nl&#nl&#nl&#nl&#nl&#nlRALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone defic"
  [3]=>
  string(265) "&#nl&#nl&#nl&#nl&#nl&#nl&#nl&#nlRALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of..."
  ["description"]=>
  string(265) "&#nl&#nl&#nl&#nl&#nl&#nl&#nl&#nlRALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(143) "https://www.drugs.com/clinical_trials/marius-pharmaceuticals-announces-pilot-study-exploring-oral-testosterone-therapy-kyzatrex-male-21266.html"
  ["blog_url"]=>
  string(143) "https://www.drugs.com/clinical_trials/marius-pharmaceuticals-announces-pilot-study-exploring-oral-testosterone-therapy-kyzatrex-male-21266.html"
  [15]=>
  string(19) "2024-01-10 07:01:20"
  ["add_date"]=>
  string(19) "2024-01-10 07:01:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9096"
  ["article_id"]=>
  string(4) "9096"
  [1]=>
  string(72) "A Common Marker of Neurological Diseases May Play Role in Healthy Brains"
  ["article_title"]=>
  string(72) "A Common Marker of Neurological Diseases May Play Role in Healthy Brains"
  [2]=>
  string(150) "January 9, 2024 -- Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerat"
  ["short_description"]=>
  string(150) "January 9, 2024 -- Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerat"
  [3]=>
  string(247) "January 9, 2024 -- Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the..."
  ["description"]=>
  string(247) "January 9, 2024 -- Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(113) "https://www.drugs.com/clinical_trials/common-marker-neurological-diseases-may-play-role-healthy-brains-21260.html"
  ["blog_url"]=>
  string(113) "https://www.drugs.com/clinical_trials/common-marker-neurological-diseases-may-play-role-healthy-brains-21260.html"
  [15]=>
  string(19) "2024-01-10 05:01:31"
  ["add_date"]=>
  string(19) "2024-01-10 05:01:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9240"
  ["article_id"]=>
  string(4) "9240"
  [1]=>
  string(83) "Mass General Brigham CMIO on AI: 'exciting, but a little anxiety-provoking'"
  ["article_title"]=>
  string(83) "Mass General Brigham CMIO on AI: 'exciting, but a little anxiety-provoking'"
  [2]=>
  string(154) "For the newest in our interview series with IT leaders about artificial intelligence's potential, Dr. Rebecca Mishuris shows where MGB is getting resu"
  ["short_description"]=>
  string(154) "For the newest in our interview series with IT leaders about artificial intelligence's potential, Dr. Rebecca Mishuris shows where MGB is getting resu"
  [3]=>
  string(262) "For the newest in our interview series with IT leaders about artificial intelligence's potential, Dr. Rebecca Mishuris shows where MGB is getting results, from clinician burnout to patient experience – and she stresses the need for responsible AI.&#nl"
  ["description"]=>
  string(262) "For the newest in our interview series with IT leaders about artificial intelligence's potential, Dr. Rebecca Mishuris shows where MGB is getting results, from clinician burnout to patient experience – and she stresses the need for responsible AI.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(100) "https://www.healthcareitnews.com/news/mass-general-brigham-cmio-ai-exciting-little-anxiety-provoking"
  ["blog_url"]=>
  string(100) "https://www.healthcareitnews.com/news/mass-general-brigham-cmio-ai-exciting-little-anxiety-provoking"
  [15]=>
  string(19) "2024-01-10 01:16:09"
  ["add_date"]=>
  string(19) "2024-01-10 01:16:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9195"
  ["article_id"]=>
  string(4) "9195"
  [1]=>
  string(57) "MHRA sets out new plans to protect safety for UK patients"
  ["article_title"]=>
  string(57) "MHRA sets out new plans to protect safety for UK patients"
  [2]=>
  string(122) "MHRA sets out new plans to protect patient safety and enable access without delay for UK patients to medical technologies."
  ["short_description"]=>
  string(122) "MHRA sets out new plans to protect patient safety and enable access without delay for UK patients to medical technologies."
  [3]=>
  string(122) "MHRA sets out new plans to protect patient safety and enable access without delay for UK patients to medical technologies."
  ["description"]=>
  string(122) "MHRA sets out new plans to protect patient safety and enable access without delay for UK patients to medical technologies."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(131) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/mhra-sets-out-new-plans-to-protect-patient-safety/"
  ["blog_url"]=>
  string(131) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/mhra-sets-out-new-plans-to-protect-patient-safety/"
  [15]=>
  string(19) "2024-01-10 00:55:50"
  ["add_date"]=>
  string(19) "2024-01-10 00:55:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:42"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9196"
  ["article_id"]=>
  string(4) "9196"
  [1]=>
  string(59) "Futura Medical appoints Roy Davis as non-executive director"
  ["article_title"]=>
  string(59) "Futura Medical appoints Roy Davis as non-executive director"
  [2]=>
  string(152) "Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive"
  ["short_description"]=>
  string(152) "Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive"
  [3]=>
  string(184) "Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive director with immediate effect."
  ["description"]=>
  string(184) "Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive director with immediate effect."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(131) "https://www.medicalplasticsnews.com/news/medical-plastics-company-news/futura-medical-appoints-roy-davis-as-non-executive-director/"
  ["blog_url"]=>
  string(131) "https://www.medicalplasticsnews.com/news/medical-plastics-company-news/futura-medical-appoints-roy-davis-as-non-executive-director/"
  [15]=>
  string(19) "2024-01-09 22:25:00"
  ["add_date"]=>
  string(19) "2024-01-09 22:25:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:42"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9151"
  ["article_id"]=>
  string(4) "9151"
  [1]=>
  string(108) "Bicycle Health Publishes First-Ever Peer-Reviewed Research of Telehealth Treatment for Poppy Seed Tea Misuse"
  ["article_title"]=>
  string(108) "Bicycle Health Publishes First-Ever Peer-Reviewed Research of Telehealth Treatment for Poppy Seed Tea Misuse"
  [2]=>
  string(125) "While poppy seeds are a legal substance, misuse of poppy seed tea can lead to opioid misuse, contribute to overdose and death"
  ["short_description"]=>
  string(125) "While poppy seeds are a legal substance, misuse of poppy seed tea can lead to opioid misuse, contribute to overdose and death"
  [3]=>
  string(749) "
While poppy seeds are a legal substance, misuse of poppy seed tea can lead to opioid misuse, contribute to overdose and death
"
  ["description"]=>
  string(749) "
While poppy seeds are a legal substance, misuse of poppy seed tea can lead to opioid misuse, contribute to overdose and death
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(180) "https://www.globenewswire.com/news-release/2024/01/09/2806337/0/en/Bicycle-Health-Publishes-First-Ever-Peer-Reviewed-Research-of-Telehealth-Treatment-for-Poppy-Seed-Tea-Misuse.html"
  ["blog_url"]=>
  string(180) "https://www.globenewswire.com/news-release/2024/01/09/2806337/0/en/Bicycle-Health-Publishes-First-Ever-Peer-Reviewed-Research-of-Telehealth-Treatment-for-Poppy-Seed-Tea-Misuse.html"
  [15]=>
  string(19) "2024-01-09 22:00:00"
  ["add_date"]=>
  string(19) "2024-01-09 22:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9279"
  ["article_id"]=>
  string(4) "9279"
  [1]=>
  string(66) "Medical Device Manufacturer Plans $88 Million Expansion in Atlanta"
  ["article_title"]=>
  string(66) "Medical Device Manufacturer Plans $88 Million Expansion in Atlanta"
  [2]=>
  string(158) "&#nl        PEACHTREE CITY, GA—A German drug packaging and medical device manufacturer is investing $88 million to build a new assembly plant here and "
  ["short_description"]=>
  string(158) "&#nl        PEACHTREE CITY, GA—A German drug packaging and medical device manufacturer is investing $88 million to build a new assembly plant here and "
  [3]=>
  string(208) "&#nl        
PEACHTREE CITY, GA—A German drug packaging and medical device manufacturer is investing $88 million to build a new assembly plant here and hire more than 200 new employees.
&#nl      "
  ["description"]=>
  string(208) "&#nl        
PEACHTREE CITY, GA—A German drug packaging and medical device manufacturer is investing $88 million to build a new assembly plant here and hire more than 200 new employees.
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(108) "https://www.assemblymag.com/articles/98256-medical-device-manufacturer-plans-88-million-expansion-in-atlanta"
  ["blog_url"]=>
  string(108) "https://www.assemblymag.com/articles/98256-medical-device-manufacturer-plans-88-million-expansion-in-atlanta"
  [15]=>
  string(19) "2024-01-09 18:05:00"
  ["add_date"]=>
  string(19) "2024-01-09 18:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:31"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:31"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9280"
  ["article_id"]=>
  string(4) "9280"
  [1]=>
  string(69) "Contact Lens Manufacturer Employs Solar Power to Safeguard Production"
  ["article_title"]=>
  string(69) "Contact Lens Manufacturer Employs Solar Power to Safeguard Production"
  [2]=>
  string(158) "&#nl        LAKE FOREST, CA—Staar Surgical, a manufacturer of implantable lenses used in ophthalmic surgery, has inaugurated a 1.1 megawatt solar energ"
  ["short_description"]=>
  string(158) "&#nl        LAKE FOREST, CA—Staar Surgical, a manufacturer of implantable lenses used in ophthalmic surgery, has inaugurated a 1.1 megawatt solar energ"
  [3]=>
  string(380) "&#nl        
LAKE FOREST, CA—Staar Surgical, a manufacturer of implantable lenses used in ophthalmic surgery, has inaugurated a 1.1 megawatt solar energy microgrid at its production facility here. The system was installed to reduce energy costs, improve sustainability, and safeguard production in the event of grid outages caused by extreme weather events.
&#nl      "
  ["description"]=>
  string(380) "&#nl        
LAKE FOREST, CA—Staar Surgical, a manufacturer of implantable lenses used in ophthalmic surgery, has inaugurated a 1.1 megawatt solar energy microgrid at its production facility here. The system was installed to reduce energy costs, improve sustainability, and safeguard production in the event of grid outages caused by extreme weather events.
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(112) "https://www.assemblymag.com/articles/98254-contact-lens-manufacturer-employs-solar-power-to-safeguard-production"
  ["blog_url"]=>
  string(112) "https://www.assemblymag.com/articles/98254-contact-lens-manufacturer-employs-solar-power-to-safeguard-production"
  [15]=>
  string(19) "2024-01-09 16:03:00"
  ["add_date"]=>
  string(19) "2024-01-09 16:03:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:31"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:31"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9068"
  ["article_id"]=>
  string(4) "9068"
  [1]=>
  string(118) "FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease"
  ["article_title"]=>
  string(118) "FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease"
  [2]=>
  string(150) "PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focuse"
  ["short_description"]=>
  string(150) "PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focuse"
  [3]=>
  string(252) "PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical..."
  ["description"]=>
  string(252) "PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(44) "https://www.drugs.com/nda/sgx945_240108.html"
  ["blog_url"]=>
  string(44) "https://www.drugs.com/nda/sgx945_240108.html"
  [15]=>
  string(19) "2024-01-09 06:01:23"
  ["add_date"]=>
  string(19) "2024-01-09 06:01:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9097"
  ["article_id"]=>
  string(4) "9097"
  [1]=>
  string(119) "Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause"
  ["article_title"]=>
  string(119) "Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause"
  [2]=>
  string(150) "Berlin, January 8, 2024 – Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program "
  ["short_description"]=>
  string(150) "Berlin, January 8, 2024 – Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program "
  [3]=>
  string(251) "Berlin, January 8, 2024 – Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled..."
  ["description"]=>
  string(251) "Berlin, January 8, 2024 – Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(142) "https://www.drugs.com/clinical_trials/bayer-starts-phase-ii-study-nirvana-evaluate-elinzanetant-women-sleep-disturbances-associated-21262.html"
  ["blog_url"]=>
  string(142) "https://www.drugs.com/clinical_trials/bayer-starts-phase-ii-study-nirvana-evaluate-elinzanetant-women-sleep-disturbances-associated-21262.html"
  [15]=>
  string(19) "2024-01-09 05:01:49"
  ["add_date"]=>
  string(19) "2024-01-09 05:01:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}